ABSTRACT. In the treatment of osteoporosis, the tolerance of oral bisphosphonates is often low. The high potency of ibandronate allows iv bolus injections that can be repeated every 2 to 3 months. However, the best dose and time interval of the treatment with iv ibandronate is still debated. Efficacy of 2-mg ibandronate injected every 3 months was tested in men with osteoporosis over 2 yr, in a prospective, open study. Fourteen men with primary osteoporosis, mean age 57±12 yr (range: 40-73), received 2-mg ibandronate iv every 3 months over 2 yr. All got 1 g/day calcium and 880 UI/day vitamin D for 2 yr. Bone mineral density (BMD) increased after 2 yr by 6.7±1.5% (mean change±SEM) at lumbar spine (p<0.001), by 3.2±08% at trochanter (p<0.001) and by 1.4±1.1% at femoral neck (ns). Serum`-crosslaps and osteocalcin decreased significantly by 30-45 and 30%, respectively, during the 2 yr of treatment. Serum calcium increased from the lower to the middle tertile of the normal range during the 2 yr of the study. The observed decrease of bone remodelling and the increase of BMD are of the same magnitude as those described with oral bisphosphonates. The increase of plasma calcium confirms the positive effect of the supplementation with calcium and vitamin D. These results suggest that 3 months are a good interval between two doses of iv ibandronate, when 2 mg are given. (J. Endocrinol. Invest. 26: 728-732, 2003) 
INTRODUCTION
Osteoporosis is less common in men than in women, but approximately 25 to 30% of all hip fractures occur in men, and many men have vertebral deformities (1, 2). The causes of osteoporosis in men include excess of glucocorticoids, hypogonadism, and a variety of other systemic conditions, medications and lifestyle factors; in about 50% there is no obvious cause. Only few therapies have been evaluated in men. Testosterone therapy has limited efficacy in men with hypogonadism (3). Alendronate significantly increased spine and hip bone mineral density (BMD), and decreased the incidence of vertebral fractures (4). However, bisphosphonates cause gastrointestinal side effects in many patients (5), and must be taken under strict conditions, which affects compliance. These limitations led to the investigation of intermittent iv administration of aminobisphosphonate, which showed an increase in BMD of the spine and femoral neck after 3 monthly infusions of pamidronate and ibandronate (6, 7). Ibandronate [1-hydroxy-3-(methylpentylamino)-propylidene bisphosphonates] is a potent aminobisphosphonate with proven efficacy in the treatment of malignant hypercalcemia (8) and of post-menopausal osteoporosis (9). For the treatment of osteoporosis, iv ibandronate, 2 mg every 3 months as bolus injection, seems to be effective (7). The goal of the present open pilot study was to investigate the effect of 2 mg of ibandronate, administered every 3 months over 2 yr, on BMD and on biochemical markers of bone metabolism in men with primary osteoporosis.
MATERIALS AND METHODS

Study subjects
The patients (age 40 to 80 yr) were referred to the out-patient clinic for osteoporosis at the University Hospital of Lausanne, Switzerland. This pilot study was open and monocentric. The inclusion criteria were the presence of one osteoporosis fracture (vertebra, femoral neck or wrist) and a BMD at the lumbar spine of at least 1 SD below the Z-score, or at least 1.5 SD below the Z-score without any fracture. Men with secondary causes of os- (hypogonadism, hyperparathyroidism, hyperthyroidism, etc.) , medication affecting bone metabolism (corticosteroids or cyclosporine during the preceding 6 months; calcitonin, fluor or bisphosphonates during the preceding 12 months), a history of cancer other than basal-cell carcinoma of the skin, or a severe disability disease with a life expectancy of less than 2 yr. All patients had given their written informed consent prior to enrolment. The study was approved by the local Ethics Committee.
Treatment
All patients included in this study received 2-mg ibandronate every 3 months as a bolus injection at 0, 3, 6, 9, 12, 15, 18 and 21 months. All got oral supplementation with 1000-mg calcium and 880-UI vitamin D every day during the 2 yr of treatment.
Baseline and follow-up study
In the pre-treatment period, a complete history was obtained, and each patient underwent a physical examination, electrocardiography, chest radiography, and serum parameters [osteocalcin, C-telopeptides, PTH, 25 (OH) vitamin D and 1,25 (OH) vitamin D, complete blood cell count, electrolytes, creatinine, albumine, liver-function tests]. The patients included returned for visits, biochemical measurements and treatment at 0, 3, 6, 9, 12, 15, 18, 21 and 24 months. The BMD of the lumbar spine (anteroposterior view), femoral neck, trochanter and distal forearm was measured by dual-energy X-ray absorptiometry (Hologic QDR 2000) at baseline and at 6, 12, 18 and 24 months. Quality control of the BMD measurements, including teaching of relevant technicians and phantom assessments, was performed before and throughout the study by checking accuracy and reproducibility on a daily basis. The precision of our Hologic QDR 2000 equipment was 1.3% at the lumbar spine, 1.8% at the femoral neck and 1.9% at the trochanter (7). The precision was evaluated by repeated measurement in 10 subjects (4 measurements per subject) according to Gluer et al. (10) . The long-term stability was monitored during the study by measuring an object of constant mass (European spine phantom) on daily basis. The device showed a high stability during all the study with an in vitro long-term reproducibility between 0.37 and 0.47% in BMD per year. All scans were reviewed by a blinded expert, and reanalyzed upon request. BMD is expressed in grams of hydroxyapatite per cm 2 . Posteroanterior and lateral radiographs of the lumbar and thoracic spine were obtained at base line and after 2 yr of treatment. All radiographs were reviewed by a blinded expert. Fasting serum samples were obtained in the morning for the measurement of calcium corrected for albumine, phosphate, creatinine, alkaline phosphatase, osteocalcin, `-crosslaps, PTH. Plasma 25 (OH) vitamin D, and 1,25 (OH) vitamin D were measured on fasting serum sample at baseline and at 12 months. These parameters were determined by the following methods: osteocalcin by a two-site radioimmunoassay as described by Garnero et al. (11) (Elsa-Osteo, CIS bio international, Gif-surYvette, France; normal 9.6 to 26.8 ng/ml for men >30 yr); serum -crosslaps by a two-site radioimmunoassay (Systèmes Elecsys 1010/1020, Roche Diagnostics, Meylan, France); intact PTH with an immunoradiometric assay (Nichols Institute, San Juan Capistrano, California; intact PTH 100T Kit; normal 10 to 65 pg/ml); 25 (OH) vitamin D with a radioimmunoassay (DiaSorin, Stillwater, Minnesota, normal 8.4 to 52.3 μg/l); 1,25 (OH) vitamin D with a radioimmunoassay (Incstar corporation, Stillwater, Minnesota). The correction of the serum calcium by albumine (normal 2.1 to 2.5 mmol/l) was done according to statistics established by the laboratory of the hospital (12): measured calcium -0.012 [measured albumine -39.5 (g/l) ]. Safety parameters measured included serum creatinine, sodium, potassium, alanine aminotransferase, aspartate aminotransferase, gamma-GT and complete blood count. All these latter determinations were done by routine laboratory methods.
Statistical analysis
The primary endpoint of the study was the lumbar spine BMD and the secondary endpoint was the effects on osteocalcin and -crosslaps. The analysis of BMD variables, osteocalcin and `-crosslaps were based on the percent changes from baseline. Statistical differences were evaluated by paired t-test. P values <0.05 were considered to be significant.
RESULTS
Fourteen consecutive male patients with primary osteoporosis were included in this study. Patient characteristics at baseline are given in Table 1 . At entrance, 9 patients had experienced 18 vertebral fractures and 4 non-vertebral fractures (wrist 3; upper arm 1). All these fractures occurred, either spontaneously or after a minor trauma. Nine patients had a T-score below -2.5 DS either at the lumbar spine or femoral neck.
BMD
The BMD of the lumbar spine and of the trochanter increased significantly by 6.7±1.5% and by 3.2±0.8% (percent change, mean±SEM) after 2 yr of treatment (Fig. 1) . The BMD of the femoral neck and the total hip (Fig. 2) increased by 1.4±1.1% and 0.9±0.6%, respectively. The BMD of the distal forearm increased by 1.5±0.5% (ns, data not shown).
Biochemical markers
As shown in Figure 3 , there was a progressive decrease in bone serum `-crosslaps reaching a nadir between 9 and 12 months, and a slight increase 
